Salvage Chemoradiation Therapy With Triple-Drug Combination (Docetaxel, 5-FU, and CDDP) for Postoperative Locoregional Recurrence pf Esophageal Cancer

Abstract

Purpose/Objective(s)Locoregional recurrence (LR) is a common failure in patients after surgery for locally advanced resectable esophageal cancer. The aim of this retrospective study was to assess the efficacy of salvage radiation therapy (RT) or concurrent multiple drug chemoradiation therapy (CRT) with for LR of esophageal cancer after curative surgery.Materials/MethodsSeventeen patients who received salvage RT or CRT for LR of esophageal squamous cell cancer after curative surgery between April 2006 and September 2013 at Tokushima University Hospital were reviewed. All patients received external beam RT using a linear accelerator with a photon-beam energy of 6-10MV. The prescribed total dose was 50-60Gy (median, 60Gy). Concurrent triple-drug combination chemotherapy with Docetaxel, 5-FU and CDDP (DFP) was administrated to 10 patients and S-1 to 4 patients. Three patients were undergone without concurrent chemotherapy during radiation therapy period.ResultsMedian follow-up periods were 16.7 months for all evaluable patients. The overall 1-and 3-year survival rates were 68.0%and 49.6%, respectively. In concurrent DFP group, the 3-year survival rates was 80%, significantly higher survival rate compared with non-DFP group (0%, p = 0.006). Grade 3 leukocytopenia was observed in 41% of the patients with concurrent DFP.ConclusionsScientific Abstract 2334; TableG3/G4 Toxicity with or without concurrent DFP chemoradiation therapyToxicityG3G4Acute phase Leukocytopenia7 (41%)0 Thrombocytopenia00 Anemia00 Nausea2 (12%)0Late phase Heart00 Radiation pneumonitis00 Esophageal stenosis (anastomosis site irradiation, n = 6)00 Open table in a new tab Purpose/Objective(s)Locoregional recurrence (LR) is a common failure in patients after surgery for locally advanced resectable esophageal cancer. The aim of this retrospective study was to assess the efficacy of salvage radiation therapy (RT) or concurrent multiple drug chemoradiation therapy (CRT) with for LR of esophageal cancer after curative surgery. Locoregional recurrence (LR) is a common failure in patients after surgery for locally advanced resectable esophageal cancer. The aim of this retrospective study was to assess the efficacy of salvage radiation therapy (RT) or concurrent multiple drug chemoradiation therapy (CRT) with for LR of esophageal cancer after curative surgery. Materials/MethodsSeventeen patients who received salvage RT or CRT for LR of esophageal squamous cell cancer after curative surgery between April 2006 and September 2013 at Tokushima University Hospital were reviewed. All patients received external beam RT using a linear accelerator with a photon-beam energy of 6-10MV. The prescribed total dose was 50-60Gy (median, 60Gy). Concurrent triple-drug combination chemotherapy with Docetaxel, 5-FU and CDDP (DFP) was administrated to 10 patients and S-1 to 4 patients. Three patients were undergone without concurrent chemotherapy during radiation therapy period. Seventeen patients who received salvage RT or CRT for LR of esophageal squamous cell cancer after curative surgery between April 2006 and September 2013 at Tokushima University Hospital were reviewed. All patients received external beam RT using a linear accelerator with a photon-beam energy of 6-10MV. The prescribed total dose was 50-60Gy (median, 60Gy). Concurrent triple-drug combination chemotherapy with Docetaxel, 5-FU and CDDP (DFP) was administrated to 10 patients and S-1 to 4 patients. Three patients were undergone without concurrent chemotherapy during radiation therapy period. ResultsMedian follow-up periods were 16.7 months for all evaluable patients. The overall 1-and 3-year survival rates were 68.0%and 49.6%, respectively. In concurrent DFP group, the 3-year survival rates was 80%, significantly higher survival rate compared with non-DFP group (0%, p = 0.006). Grade 3 leukocytopenia was observed in 41% of the patients with concurrent DFP. Median follow-up periods were 16.7 months for all evaluable patients. The overall 1-and 3-year survival rates were 68.0%and 49.6%, respectively. In concurrent DFP group, the 3-year survival rates was 80%, significantly higher survival rate compared with non-DFP group (0%, p = 0.006). Grade 3 leukocytopenia was observed in 41% of the patients with concurrent DFP. ConclusionsScientific Abstract 2334; TableG3/G4 Toxicity with or without concurrent DFP chemoradiation therapyToxicityG3G4Acute phase Leukocytopenia7 (41%)0 Thrombocytopenia00 Anemia00 Nausea2 (12%)0Late phase Heart00 Radiation pneumonitis00 Esophageal stenosis (anastomosis site irradiation, n = 6)00 Open table in a new tab